Embla Medical hf 2022 AR2
The report highlights Össur's financial and sustainability performance for the fiscal year 2022. During the year, the company achieved 4% organic sales growth, reaching USD 719 million in net sales, and successfully launched its next-generation Power Knee globally. Össur remained carbon neutral for Scope 1 and 2, and selected Scope 3 emissions, while sourcing 99% of its electricity from renewable sources. Additionally, the company expanded its product portfolio through the acquisition of Naked Prosthetics, strengthening its upper limb offering.
Company: Embla Medical hf
Sector: Health Care
Country: Iceland
Year: 2022
Type: AR2
Pages: 131
Embla Medical hf
Annual Report
The report highlights Össur's financial and sustainability performance for the fiscal year 2022. During the year, the company achieved 4% organic sales growth, reaching USD 719 million in net sales, and successfully launched its next-generation Power Knee globally. Össur remained carbon neutral for Scope 1 and 2, and selected Scope 3 emissions, while sourcing 99% of its electricity from renewable sources. Additionally, the company expanded its product portfolio through the acquisition of Naked Prosthetics, strengthening its upper limb offering.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees